Journal
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
Volume 8, Issue 1, Pages 4-11Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040622316672544
Keywords
cholesterol; dyslipidaemias; ezetimibe; hypercholesterolaemias; hyperlipidaemia; lipids; low-density lipoprotein
Categories
Ask authors/readers for more resources
The aim of pharmacological lipid modification is to reduce low-density lipoprotein cholesterol (LDL-C) as a means of either secondary or primary prevention of cardiovascular disease. Statins are the first-line therapy for pharmacological lipid modification. Ezetimibe is a drug which reduces LDL-C by selectively inhibiting intestinal cholesterol absorption. This provides an alternative pharmacological approach to that of statin therapy to reduce LDL-C. Ezetimibe has been shown to significantly reduce levels of LDL-C and recently, as demonstrated in the IMPROVE-IT trial, to reduce the rate of cardiovascular events in high-risk patients. Ezetimibe therefore has an important role in pharmacological lipid modification. In this paper, we examine the body of research behind ezetimibe and assess its current clinical applications in different patient subgroups.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available